PUBLISHER: Grand View Research | PRODUCT CODE: 2040565
PUBLISHER: Grand View Research | PRODUCT CODE: 2040565
The global single-use bioprocessing connectors market size was valued at USD 1.4 billion in 2025 and is expected to reach USD 4.2 billion by 2033, growing at a CAGR of 14.1% from 2026 to 2033. This growth is driven by the increasing adoption of single-use bioprocessing systems, the rising production of biologics and biosimilar, and continuous advancements in connector design and functionality.
Growing emphasis on reducing contamination risks and improving operational efficiency. The evolution of single-use bioprocessing connectors has been driven by advancements in design, materials, and automation, enhancing sterility, efficiency, and scalability in biopharmaceutical manufacturing. Advanced aseptic connectors feature double sterile barriers, integrated seals, and self-closing mechanisms to prevent contamination. The advanced products also feature genderless designs that eliminate the need for male/female configurations, simplifying assembly and reducing human error. For instance, in April 2023, Colder Products Company announced the launch of its AseptiQuik W Series aseptic connectors. These connectors are notable for being the industry's largest genderless aseptic connectors, featuring a 1-1/2-inch flow path that facilitates the transfer of hundreds of liters per minute. This is aimed at significantly reducing fluid transfer times in bioprocesses. These technological advancements align closely with the broader market growth, which is driven by the increasing adoption of single-use systems and the rising production of biologics and biosimilar. The growing complexity of biopharmaceutical processes has intensified the demand for reliable, sterile, and scalable fluid transfer solutions. Advanced connector systems play a critical role in enabling closed-system processing, thereby enhancing operational efficiency and ensuring compliance with stringent regulatory standards.
Moreover, the rapid expansion of the biopharmaceutical industry continues to reinforce market demand. In 2024, a total of 50 new therapeutics were approved by the FDA, including 10 monoclonal antibodies and 3 bispecific antibodies, which together accounted for a significant share of protein-based drug approvals. The increasing focus on monoclonal antibodies and advanced therapies has accelerated the need for single-use technologies, including connectors for aseptic fluid transfer. For instance, Lynx CDR connectors offered by Merck KGaA are specifically designed for efficient bulk fluid transfer in large-scale monoclonal antibody production, further supporting the adoption of advanced bioprocessing solutions.
In addition, increasing outsourcing of biopharmaceutical manufacturing to contract development and manufacturing organizations (CDMOs). These facilities require highly flexible and scalable production systems to accommodate multiple clients and products, making single-use technologies an ideal solution. Single-use connectors enable faster changeovers, reduce the risk of cross-contamination, and support efficient multi-product operations. So, the growing reliance on CDMOs is further accelerating the adoption of single-use bioprocessing connectors across the industry.
Global Single-use Bioprocessing Connectors Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and analyzes the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global single-use bioprocessing connectors market by product, application, end-use, and region: